Hybrid Nanoparticles as Theranostics Platforms for Glioblastoma Treatment: Phototherapeutic and X-ray Phase Contrast Tomography Investigations
Abstract
:1. Introduction
2. Materials and Methods
2.1. Nanoplatform Synthesis and Characterization
2.2. Detection of 1O2 Generation
2.3. In Vivo and Ex Vivo Experiments
2.3.1. Imaging
2.3.2. Therapeutic Treatment
2.3.3. X-ray Phase-Contrast Tomography
3. Results
3.1. Nanoplatform Synthesis and Characterization
3.2. Singlet Oxygen Studies
3.3. In Vivo Imaging
3.4. In Vivo Phototherapeutic Treatment
3.5. X-ray Phase-Contrast Tomography Investigations
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 2007, 114, 97–109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schwartzbaum, J.A.; Fisher, J.L.; Aldape, K.D.; Wrensch, M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pr. Cardiovasc. Med. 2006, 2, 494–503. [Google Scholar] [CrossRef]
- Thakkar, J.P.; Dolecek, T.A.; Horbinski, C.; Ostrom, Q.T.; Lightner, D.D.; Barnholtz-Sloan, J.; Villano, J.L. Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiol. Biomark. Prev. 2014, 23, 1985–1996. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hardee, M.E.; Zagzag, D. Mechanisms of Glioma-Associated Neovascularization. Am. J. Pathol. 2012, 181, 1126–1141. [Google Scholar] [CrossRef] [Green Version]
- Jain, R.K.; Di Tomaso, E.; Duda, D.G.; Loeffler, J.S.; Sorensen, A.G.; Batchelor, T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007, 8, 610–622. [Google Scholar] [CrossRef] [PubMed]
- Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10, 459–466. [Google Scholar] [CrossRef]
- Koshy, M.; Villano, J.L.; Dolecek, T.A.; Howard, A.; Mahmood, U.; Chmura, S.J.; Weichselbaum, R.R.; McCarthy, B.J. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Neuro-Oncol. 2011, 107, 207–212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tran, B.; Rosenthal, M.A. Survival comparison between glioblastoma multiforme and other incurable cancers. J. Clin. Neurosci. 2010, 17, 417–421. [Google Scholar] [CrossRef]
- Legler, J.M.; Ries, L.A.G.; Smith, M.A.; Warren, J.L.; Heineman, E.F.; Kaplan, R.S.; Linet, M.S. Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality. J. Natl. Cancer Inst. 1999, 91, 1382–1390. [Google Scholar] [CrossRef]
- De Paula, L.B.; Primo, F.L.; Tedesco, A.C. Nanomedicine associated with photodynamic therapy for glioblastoma treatment. Biophys. Rev. 2017, 9, 761–773. [Google Scholar] [CrossRef]
- Silbergeld, D.L.; Chicoine, M.R. Isolation and characterization of human malignant glioma cells from histologically normal brain. J. Neurosurg. 1997, 86, 525–531. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dupont, C.; Vermandel, M.; Leroy, H.-A.; Quidet, M.; Lecomte, F.; Delhem, N.; Mordon, S.; Reyns, N. INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): Study Protocol for a Phase I Clinical Trial. Neurosurgery 2018, 84, E414–E419. [Google Scholar] [CrossRef] [Green Version]
- Dolmans, D.E.J.G.J.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380–387. [Google Scholar] [CrossRef] [PubMed]
- Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part one—Photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 2004, 1, 279–293. [Google Scholar] [CrossRef] [Green Version]
- McKenzie, L.K.; Bryant, H.E.; Weinstein, J.A. Transition metal complexes as photosensitisers in one- and two-photon photodynamic therapy. Co-ord. Chem. Rev. 2019, 379, 2–29. [Google Scholar] [CrossRef] [Green Version]
- Zhao, J.; Wu, W.; Sun, J.; Guo, S. Triplet photosensitizers: From molecular design to applications. Chem. Soc. Rev. 2013, 42, 5323–5351. [Google Scholar] [CrossRef]
- Baggaley, E.; Weinstein, J.A.; Williams, J.A.G. Lighting the way to see inside the live cell with luminescent transition metal complexes. Co-ord. Chem. Rev. 2012, 256, 1762–1785. [Google Scholar] [CrossRef]
- Ko, C.-N.; Li, G.; Leung, C.-H.; Ma, D.-L. Dual function luminescent transition metal complexes for cancer theranostics: The combination of diagnosis and therapy. Co-ord. Chem. Rev. 2018, 381, 79–103. [Google Scholar] [CrossRef]
- Monro, S.; Colón, K.L.; Yin, H.; Roque, J., III; Konda, P.; Gujar, S.; Thummel, R.P.; Lilge, L.; Cameron, C.G.; McFarland, S.A. Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433. Chem. Rev. 2019, 119, 797–828. [Google Scholar] [CrossRef]
- Norouzi, M.; Amerian, M.; Amerian, M.; Atyabi, F. Clinical applications of nanomedicine in cancer therapy. Drug Discov. Today 2020, 25, 107–125. [Google Scholar] [CrossRef]
- Wong, X.Y.; Sena-Torralba, A.; Álvarez-Diduk, R.; Muthoosamy, K.; Merkoçi, A. Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs. ACS Nano 2020, 14, 2585–2627. [Google Scholar] [CrossRef] [PubMed]
- Giner-Casares, J.J.; Henriksen-Lacey, M.; Coronado-Puchau, M.; Liz-Marzán, L.M. Inorganic nanoparticles for biomedicine: Where materials scientists meet medical research. Mater. Today 2015, 19, 19–28. [Google Scholar] [CrossRef]
- Bobo, D.; Robinson, K.J.; Islam, J.; Thurecht, K.J.; Corrie, S.R. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm. Res. 2016, 33, 2373–2387. [Google Scholar] [CrossRef]
- Moreira, A.F.; Rodrigues, C.F.; Reis, C.A.; Costa, E.C.; Correia, I.J. Gold-core silica shell nanoparticles application in imaging and therapy: A review. Microporous Mesoporous Mater. 2018, 270, 168–179. [Google Scholar] [CrossRef]
- Louis, C.; Pluchery, O. Gold Nanoparticles in the Past: Before the Nanotechnology Era. In Gold Nanoparticles for Physics, Chemistry and Biology; World Scientific: Singapore, 2012. [Google Scholar]
- Hutter, E.; Fendler, J.H. Exploitation of Localized Surface Plasmon Resonance. Adv. Mater. 2004, 16, 1685–1706. [Google Scholar] [CrossRef]
- Huang, X.; Jain, P.K.; El-Sayed, I.H.; El-Sayed, M.A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 2008, 23, 217–228. [Google Scholar] [CrossRef]
- Jaque, D.; Martínez Maestro, L.; del Rosal, B.; Haro-Gonzalez, P.; Benayas, A.; Plaza, J.L.; Rodríguez, E.M.; Solé, J.G. Nanoparticles for photothermal therapies. Nanoscale 2014, 6, 9494–9530. [Google Scholar] [CrossRef]
- Hu, Q.; Huang, Z.; Duan, Y.; Fu, Z.; Liu, B. Reprogramming Tumor Microenvironment with Photothermal Therapy. Bioconjugate Chem. 2020, 31, 1268–1278. [Google Scholar] [CrossRef]
- Vivero-Escoto, J.L.; Huxford-Phillips, R.C.; Lin, W. Silica-based nanoprobes for biomedical imaging and theranostic applications. Chem. Soc. Rev. 2012, 41, 2673–2685. [Google Scholar] [CrossRef] [Green Version]
- Ricciardi, L.; Sancey, L.; Palermo, G.; Termine, R.; De Luca, A.; Szerb, E.I.; Aiello, I.; Ghedini, M.; Strangi, G.; La Deda, M. Plasmon-mediated cancer phototherapy: The combined effect of thermal and photodynamic processes. Nanoscale 2017, 9, 19279–19289. [Google Scholar] [CrossRef]
- Ricciardi, L.; Mastropietro, T.F.; Ghedini, M.; La Deda, M.; Szerb, E.I. Ionic-pair effect on the phosphorescence of ionic iridium(III) complexes. J. Organomet. Chem. 2014, 772–773, 307–313. [Google Scholar] [CrossRef]
- Zhang, W.; Jian, J.; Sun, C.; Chen, J.; Lv, W.; Sun, M.; Zhao, Y.; Zhao, Q.; Hu, C. High-resolution 3D imaging of microvascular architecture in human glioma tissues using X-ray phase-contrast computed tomography as a potential adjunct to histopathology. Int. J. Imaging Syst. Technol. 2020, 30, 464–472. [Google Scholar] [CrossRef]
- Momose, A.; Takeda, T.; Itai, Y.; Hirano, K. Phase–contrast X–ray computed tomography for observing biological soft tissues. Nat. Med. 1996, 2, 473–475. [Google Scholar] [CrossRef] [PubMed]
- Krajczewski, J.; Rucińska, K.; Townley, H.E.; Kudelski, A. Role of various nanoparticles in photodynamic therapy and detection methods of singlet oxygen. Photodiagnosis Photodyn. Ther. 2019, 26, 162–178. [Google Scholar] [CrossRef] [PubMed]
- Bravin, A.; Coan, P.; Suortti, P. X-ray phase-contrast imaging: From pre-clinical applications towards clinics. Phys. Med. Biol. 2012, 58, R1–R35. [Google Scholar] [CrossRef] [PubMed]
- Paganin, D. Coherent X-ray Optics, 6th ed.; Oxford University Press: Oxford, UK, 2006. [Google Scholar]
- Brun, F.; Massimi, L.; Fratini, M.; Dreossi, D.; Billé, F.; Accardo, A.; Pugliese, R.; Cedola, A. SYRMEP Tomo Project: A graphical user interface for customizing CT reconstruction workflows. Adv. Struct. Chem. Imaging 2017, 3, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, B.; Yin, J.-J.; Bilski, P.J.; Chignell, C.F.; Roberts, J.E.; He, Y.-Y. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol. Appl. Pharmacol. 2009, 241, 163–172. [Google Scholar] [CrossRef] [Green Version]
- Rojiani, A.M.; Dorovini-Zis, K. Glomeruloid vascular structures in glioblastoma multiforme: An immunohistochemical and ultrastructural study. J. Neurosurg. 1996, 85, 1078–1084. [Google Scholar] [CrossRef]
- Chakrabarti, M.I.; Banik, N.L.; Ray, S.K. Photofrin Based Photodynamic Therapy and miR-99a Transfection Inhibited FGFR3 and PI3K/Akt Signaling Mechanisms to Control Growth of Human Glioblastoma In Vitro and In Vivo. PLoS ONE 2013, 8, e55652. [Google Scholar] [CrossRef]
- Schumacker, P.T. Reactive Oxygen Species in Cancer: A Dance with the Devil. Cancer Cell 2015, 27, 156–157. [Google Scholar] [CrossRef] [Green Version]
- Galadari, S.; Rahman, A.; Pallichankandy, S.; Thayyullathil, F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Radic. Biol. Med. 2017, 104, 144–164. [Google Scholar] [CrossRef] [PubMed]
- Prasad, S.; Gupta, S.C.; Tyagi, A.K. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer Lett. 2016, 387, 95–105. [Google Scholar] [CrossRef]
- Liu, Y.; Meng, X.; Bu, W. Upconversion-based photodynamic cancer therapy. Co-ord. Chem. Rev. 2019, 379, 82–98. [Google Scholar] [CrossRef]
- Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part three—Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn. Ther. 2005, 2, 91–106. [Google Scholar] [CrossRef] [Green Version]
- Castano, A.P.; Mroz, P.; Hamblin, M.R. Photodynamic therapy and anti-tumour immunity. Nat. Cancer 2006, 6, 535–545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Montalti, M.; Credi, A.; Prodi, L.; Gandolfi, M.T. Handbook of Photochemistry, 3rd ed.; CRC Press: Boca Raton, FL, USA, 2006; ISBN 978-0-429-11538-7. [Google Scholar]
- Golombek, S.K.; May, J.-N.; Theek, B.; Appold, L.; Drude, N.; Kiessling, F.; Lammers, T. Tumor targeting via EPR: Strategies to enhance patient responses. Adv. Drug Deliv. Rev. 2018, 130, 17–38. [Google Scholar] [CrossRef] [PubMed]
- Kalyane, D.; Raval, N.; Maheshwari, R.; Tambe, V.; Kalia, K.; Tekade, R.K. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater. Sci. Eng. C 2019, 98, 1252–1276. [Google Scholar] [CrossRef]
- Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [Google Scholar] [CrossRef]
- Alphandéry, E. Nano-Therapies for Glioblastoma Treatment. Cancers 2020, 12, 242. [Google Scholar] [CrossRef] [Green Version]
- Seo, B.; Lim, K.; Kim, S.S.; Oh, K.T.; Lee, E.S.; Choi, H.-G.; Shin, B.S.; Youn, Y.S. Small gold nanorods-loaded hybrid albumin nanoparticles with high photothermal efficacy for tumor ablation. Colloids Surf. B Biointerfaces 2019, 179, 340–351. [Google Scholar] [CrossRef]
- Lee, C.; Hwang, H.S.; Lee, S.; Kim, B.; Kim, J.O.; Oh, K.T.; Lee, E.S.; Choi, H.-G.; Youn, Y.S. Rabies Virus-Inspired Silica-Coated Gold Nanorods as a Photothermal Therapeutic Platform for Treating Brain Tumors. Adv. Mater. 2017, 29. [Google Scholar] [CrossRef]
- Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part two—cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn. Ther. 2005, 2, 1–23. [Google Scholar] [CrossRef] [Green Version]
- Zagzag, D.; Zhong, H.; Scalzitti, J.M.; Laughner, E.; Simons, J.W.; Semenza, G.L. Expression of Hypoxia-Inducible Factor 1? In Brain Tumors: Association with Angiogenesis, Invasion, and Progression. Cancer 2000, 88, 2606–2618. [Google Scholar] [CrossRef]
- Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843–845. [Google Scholar] [CrossRef] [PubMed]
- Arum, C.-J.; Gederaas, O.A.; Larsen, E.L.P.; Randeberg, L.L.; Hjelde, A.; Krokan, H.E.; Svaasand, L.O.; Chen, D.; Zhao, C.-M. Tissue responses to hexyl 5-aminolevulinate-induced photodynamic treatment in syngeneic orthotopic rat bladder cancer model: Possible pathways of action. J. Biomed. Opt. 2011, 16, 028001. [Google Scholar] [CrossRef] [PubMed]
Sample | Concentration/mol L−1 | mol 1O2 |
---|---|---|
Ir1 | 2 × 10−5 | 5.4 × 10−8 |
Ir1-AuSiO2 | 2 × 10−5 | 2.6 × 10−8 |
Pc4 | 2 × 10−5 | 4.3 × 10−8 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ricciardi, L.; Chatterjee, S.; Palermo, G.; Szerb, E.I.; Sanna, A.; Palermo, F.; Pieroni, N.; Fratini, M.; Bartolino, R.; Cedola, A.; et al. Hybrid Nanoparticles as Theranostics Platforms for Glioblastoma Treatment: Phototherapeutic and X-ray Phase Contrast Tomography Investigations. J. Nanotheranostics 2022, 3, 1-17. https://doi.org/10.3390/jnt3010001
Ricciardi L, Chatterjee S, Palermo G, Szerb EI, Sanna A, Palermo F, Pieroni N, Fratini M, Bartolino R, Cedola A, et al. Hybrid Nanoparticles as Theranostics Platforms for Glioblastoma Treatment: Phototherapeutic and X-ray Phase Contrast Tomography Investigations. Journal of Nanotheranostics. 2022; 3(1):1-17. https://doi.org/10.3390/jnt3010001
Chicago/Turabian StyleRicciardi, Loredana, Sharmistha Chatterjee, Giovanna Palermo, Elisabeta I. Szerb, Alessia Sanna, Francesca Palermo, Nicola Pieroni, Michela Fratini, Roberto Bartolino, Alessia Cedola, and et al. 2022. "Hybrid Nanoparticles as Theranostics Platforms for Glioblastoma Treatment: Phototherapeutic and X-ray Phase Contrast Tomography Investigations" Journal of Nanotheranostics 3, no. 1: 1-17. https://doi.org/10.3390/jnt3010001